MK-0472 / Merck (MSD), Otsuka - LARVOL DELTA

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) (clinicaltrials.gov) - P1 | N=95 | Active, not recruiting | Sponsor: Merck Sharp & Dohme LLC | Recruiting ➔ Active, not recruiting | N=178 ➔ 95 | Trial completion date: Feb 2028 ➔ May 2028 | Trial primary completion date: Feb 2028 ➔ May 2028

Enrollment change • Enrollment closed • Monotherapy • Trial completion date • Trial primary completion date • Biliary Tract Cancer • Breast Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Hepatocellular Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Small Cell Lung Cancer • Solid Tumor • Triple Negative Breast Cancer • ALK • EGFR • KRAS • ROS1

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) (clinicaltrials.gov) - P1 | N=178 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | N=100 ➔ 178

Enrollment change • Oncology • Solid Tumor

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) (clinicaltrials.gov) - P1 | N=100 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Metastases • Monotherapy • Oncology • Solid Tumor

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) (clinicaltrials.gov) - P1 | N=100 | Not yet recruiting | Sponsor: Merck Sharp & Dohme LLC

Combination therapy • Metastases • Monotherapy • New P1 trial • Oncology • Solid Tumor